A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and
symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate
monotherapy in adult patients with active rheumatoid arthritis. Patients will be randomized
to receive one of 3 doses of P38 Inhibitor (4) or methotrexate. The anticipated time on study
treatment is <3 months, and the target sample size is 100-500 individuals.